Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program

NCT00495287 is registered in ClinicalTrials.gov with Northern Italy Leukemia Group as lead sponsor.

NCT NCT00495287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00495287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program
Lead sponsor
Northern Italy Leukemia Group
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
December 31, 2015
Enrollment
573 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia